Klinic prescribes the most effective FDA approved weight loss medications currently on the market
More and more, that advice describes a new way of using GLP-1s: Microdosing, or taking smaller amounts of the GLP-1 to get the benefits without as many of the potential side effects (which include things no one wants, like nausea and constipation)
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
Given the FDA's April 2026 proposal with a comment period closing June 29, 2026, this a real question for anyone starting a multi-month compounded GLP-1 program right now
However, if you or your family have a history of pancreas issues, it might be wise to avoid the drug class altogether
GLP-3, as a triple agonist targeting GLP-1, GIP, and GCG receptors, holds significant promise as a research compound in the investigation of type 2 diabetesnot only through its observed influence on glycemic parameters but also via its substantial impact on weight reduction